Gastroduodenal tolerability of lumiracoxib vs. placebo and naproxen: A pilot endoscopic study in healthy male subjects

Alimentary Pharmacology and Therapeutics

Volumn 18, Issue 5, 2003, Pages 533-541

  Rordorf, C ^a   Kellett, N ^b   Mair, S ^b   Ford, M ^c   Milosavljev, S ^a   Branson, J ^a   Scott, G ^d  

^a NOVARTIS PHARMA AG   (Switzerland)

^b Inveresk Research   (United Kingdom)

^c WESTERN GENERAL HOSPITAL   (United Kingdom)

^d Horsham Research Centre   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 1; CYCLOOXYGENASE 2 INHIBITOR; LUMIRACOXIB; NAPROXEN; THROMBOXANE B2;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG TOLERABILITY; DUODENUM; DUODENUM MUCOSA; ENZYME ASSAY; ENZYME INHIBITION; EVALUATION; FEMALE; GASTRODUODENAL EROSION; GASTROINTESTINAL ENDOSCOPY; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN EXPERIMENT; INFECTION; MALE; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; NORMAL HUMAN; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN DISEASE; STOMACH; STOMACH EROSION; STOMACH MUCOSA; STOMACH ULCER; SYMPTOM;

ADOLESCENT; ADULT; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DICLOFENAC; DOUBLE-BLIND METHOD; ENDOSCOPY, GASTROINTESTINAL; GASTROINTESTINAL DISEASES; HUMANS; INTESTINAL MUCOSA; ISOENZYMES; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NAPROXEN; ORGANIC CHEMICALS; PILOT PROJECTS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; THROMBOXANES;

EID: 0141852139     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2003.01691.x     Document Type: Article

References (41)

1. Dougados M. The role of anti-inflammatory drugs in the treatment of osteoarthritis: a European viewpoint. Clin Exp Rheumatol 2001; 19: S9-14.
2. Moskowitz RW. The role of anti-inflammatory drugs in the treatment of osteoarthritis: a United States viewpoint. Clin Exp Rheumatol 2001; 19: S3-8.
3. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature New Biol 1971; 231: 232-5.
4. Abramson SR, Weissmann G. The mechanism of action of anti-inflammatory drugs. Arthritis Rheum 1989; 32: 1-9.
5. Cryer B, Feldman M. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J Med 1998; 104: 413-21.
6. Warner TD, Giuliano F, Vojnovic I, et al. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclooxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci USA 1999; 96: 7563-8.
7. Masferrer JL, Zweifel BS, Manning PT, et al. Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. Proc Natl Acad Sci USA 1994; 91: 3228-32.
8. Bolten WW. Scientific rationale for specific inhibition of COX-2. J Rheumatol 1998; 51: 2-7.
9. Vane JR, Botting RM. The future of NSAID therapy: selective COX-2 inhibitors. Int J Clin Pract 2000; 54: 7-9.
10. Hernandez-Diaz S, Garcia Rodriguez LA. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding and perforation: an overview of epidemiological studies published in the 1990s. Arch Intern Med 2000; 160: 2093-9.
11. Griffin MR, Yared A, Ray WA. Nonsteroidal antiinflammatory drugs and acute renal failure in elderly persons. Am J Epidemiol 2000; 151: 488-96.
12. Knijff-Dutmer EA, Kalsbeek-Batenburg EM, Koerts J, van de Laar MA. Platelet function is inhibited by non-selective nonsteroidal anti-inflammatory drugs but not by cyclo-oxygenase-2-selective inhibitors in patients with rheumatoid arthritis. Rheumatology 2002; 41: 458-61.
13. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999; 340: 1888-99.
14. McCarthy DM. Comparative toxicity of nonsteroidal antiinflammatory drugs. Am J Med 1999; 107: 37-47.
15. Laine L. Nonsteroidal anti-inflammatory drug gastropathy. Gastrointest Endosc Clin N Am 1996; 6: 489-504.
16. Singh G. Recent considerations in nonsteroidal anti-inflammatory drug gastropathy. Am J Med 1998; 105: S31-8.
17. Feldman A, McMahon AT. Do cyclooxygenase-2 inhibitors provide benefits similar to those of traditional nonsteroidal anti-inflammatory drugs, with less gastrointestinal toxicity? Ann Intern Med 2000; 132: 134-43.
18. Laine L, Harper S, Simon T, et al. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase-2 specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Gastroenterology 1999; 117: 776-83.
19. Langman MJ, Jensen DM, Watson WJ, et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. J Am Med Assoc 1999; 282: 1929-33.
20. Simon LA, Weaver AL, Graham DY, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. J Am Med Assoc 1999; 282: 1921-8.
21. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000; 343: 1520-8.
22. Goldstein JL, Silverstein FE, Agrawal NM, et al. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor. Am J Gastroenterol 2000; 95: 1681-90.
23. Hawkey C, Laine L, Simon T, et al. Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2000; 43: 370-7.
24. Goldstein JL, Correa P, Zhao WW, et al. Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis. Am J Gastroenterol 2001; 96: 1019-27.
25. Mangold JB, Gu H, Rodriguez LC, Scott G, Bonner J, Rordorf C. Pharmacokinetics and metabolism of lumiracoxib in healthy male subjects. Drug Metabolism Rev 2002; 34: 141 (Abstract 281).
26. Scott G, Rordorf C Blood P, Branson J, Milosavljev S, Greig G. Dose escalation study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of COX189 in healthy subjects. Ann Rheum Dis 2002; 61: 242 (Abstract FRI0300).
27. Scott G, Rordorf C, Milosavljev S, Ferber G. Pharmacokinetics and pharmacodynamics of COX189 in patients with knee or hip osteoarthritis. Ann Rheum Dis 2002; 61: 128 (Abstract THUO233).
28. Marshall PJ, Berry C, Wasvary J, et al. The in vitro and in vivo selectivity of COX189, a new and highly selective inhibitor of COX-2. Ann Rheum Dis 2002; 61: 259 (Abstract SAT0013).
29. Simon LS, Lanza FL, Lipsky PE, et al. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor. Arthritis Rheum 1998; 41: 1591-602.
30. 1983 Metropolitan height and weight tables. Stat Bull Metrop Life Found 1983; 64: 3-9.
31. Lanza F, Royer G, Nelson R. An endoscopic evaluation of the effects of nonsteroidal anti-inflammatory drugs on the gastric mucosa. Gastrointest Endosc 1975; 21: 103-5.
32. Brideau C, Kargman S, Liu S, et al. A human whole blood assay for clinical evaluation of biochemical efficacy of cyclooxygenase inhibitors. Inflamm Res 1996; 45: 68-74.
33. Atherton CT, Jones JI, McKaig BC, et al. COX189 (lumiracoxib): An integrated study of the pharmacokinetics, potency, selectivity and effect on the gastrointestinal tract of a new selective COX-2 inhibitor. Gut 2002; 51: A18 (Abstract OP-G061).
34. Hawkey CJ, PUCCINI (Prevention of ulcers with COX189 compared with ibuprofen in NSAID investigation) Group. Reduced cumulative incidence of gastroduodenal ulcers with two doses of a new coxib, COX189 compared with standard therapeutic doses of ibuprofen in osteoarthritis patients. Gastroenterology 2002; 122: A-345 (Abstract M1732).
35. Aabakken L, Osnes M, Frenzel W. Gastrointestinal tolerability of lornoxicam compared to that of naproxen in healthy male volunteers. Aliment Pharmacol Ther 1996; 10: 151-6.
36. Taha S, McLaughlin S, Sturrock RD, Russel RI. Evaluation of the efficacy and comparative effects on gastric and duodenal mucosa of etodolac and naproxen in patients with rheumatoid arthritis using endoscopy. Br J Rheumatol 1989; 28: 329-32.
37. Watson DJ, Harper SE, Zhao PL, Quan H, Bolognese JA, Simon TJ. Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis. Arch Intern Med 2000; 160: 2998-3003.
38. Acevedo E, Castañeda O, Ugaz M, et al. Tolerability profiles of rofecoxib (Vioxx®) and Arthrotec®. A comparison of six weeks' treatment in patients with osteoarthritis. Scand J Rheumatol 2001; 30: 19-24.
39. Deeks JJ, Smith LA, Bradley MD. Efficacy, tolerability and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. Br Med J 2002; 325: 619-27.
40. Hawkey CJ. NSAIDs and COX-2 inhibitors: what can we learn from large outcomes trials? The gastroenterologist's perspective. Clin Exp Rheum 2001; 19: S23-30.
41. Wight N, Gottesdiener K, Garlick NM, et al. Rofecoxib, a COX-2 inhibitor, does not inhibit human gastric mucosal prostaglandin production. Gastroenterology 2001; 120: 867-73.